Interventions for the treatment of oral and oropharyngeal cancers: Immunotherapy/biotherapy

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Pavitt, Sue ^a   Clarkson, J E ^b   Conway, D I ^b   Glenny, A M ^b   Macluskey, M ^b   Oliver, R J ^b   Sloan, P ^b   Warnakulasuriya, S ^b   Worthington, H V ^b   Baujat, B ^b   Blackburn, T ^b   Humphris, G ^b   Hutchison, I ^b   O'Brien, C ^b   Pignon, J P ^b   Robertson, G ^b   Rogers, S ^b   Shah, J ^b   Slevin, N ^b   Soutar, D ^b   Sturgis, E ^b   Tavender, E ^b   Vermorken, J B ^b   Wardell, S ^b   Webster, K ^b   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PLACEBO; VITAMIN D;

CALCIUM INTAKE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; HUMAN; MORBIDITY; MORTALITY; NUTRITIONAL COUNSELING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RICKETS; SENSITIVITY ANALYSIS; SUN EXPOSURE; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 44949192849     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006845     Document Type: Review

References (43)

1. Bernier 2005 Bernier J. Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology?. Nature Clinical Practice. Oncology 2005;2(6):305-14.
2. Bjordal 1992 Bjordal K, Kaasa S. Psychometric validation of the EORTC Core Quality of Life Questionnaire, 30-item version and a diagnosis-specific module for head and neck cancer patients. Acta Oncologica 1992;31(3):311-21.
3. Bonner 2006 Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen B, et al.Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine 2006;354(6): 567-78.
4. Conway 2006 Conway DI, Stockton DL, Warnakulasuriya KA, Ogden G, Macpherson LM. M. Incidence of oral and oropharyngeal cancer in United Kingdom(1990-1999) - recent trends and regional variation. Oral Oncology 2006;42(6):586-92.
5. Crompton 2007 Crompton AM, Kirn DH. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Current Cancer Drug Targets 2007;7(2):133-9.
6. CRUK 2007 Cancer Research UK (CRUK). Learn about cancer: Immunotherapy. http://info.cancerresearchuk.org/cancerandresearch/ learnaboutcancer/treatment/immunotherapy/ (accessed May 2007).
7. CTCA 2007 Cancer Treatment Centers of America (CTCA). Biotherapy/immunotherapy for oral cancer. http://www.cancercenter.com/oral- cancer/biotherapyimmunotherapy. cfm (accessed 23rd May 2007).
8. Day 1992 Day GL, Blot WJ. Second primary tumors in patients with oral cancer. Cancer 1992;70(1):14-9.
9. Day 2003 Day TA, Davis BK, Gillespie MB, Joe JK, Kibbey M, Martin-Harris B, et al.Oral cancer treatment. Current Treatment Options in Oncology 2003;4(1):27-41.
10. Deleyiannis 1997 Deleyiannis FW, Weymuller EA Jr, Coltrera MD. Quality of life of disease-free survivors of advanced (stage III or IV) oropharyngeal cancer. Head & Neck 1997;19(6):466-73.
11. Fujimoto 2006 Fujimoto Y, Mizuno T, Sugiura S, Goshima F, Kohno S, Nakashima T, et al.Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Oto-Laryngologica 2006;126(10):1115-7.
12. Funk 2002 Funk G, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head & Neck 2002;24(2):165- 80.
13. Garg 2004 Garg M, Beitler JJ. Controversies in management of the neck in head and neck cancer. Current Treatment Options in Oncology 2004;5(1):35-40.
14. Haddadin 1999 Haddadin K, Soutar DS, Oliver RJ, Webster MH, Robertson AG, MacDonald DG. Improved survival for patients with clinically T1/T2, N0 tongue tumors undergoing a prophylactic neck dissection. Head & Neck 1999;21(6):517-25.
15. Haddadin 2000 Haddadin KJ, Soutar DS, Webster MH, Robertson AG, Oliver RJ, MacDonald DG. Natural history and patterns of recurrence of tongue tumours. British Journal of Plastic Surgery 2000;53(4):279-85.
16. Hammerlid 1997 Hammerlid E, Bjordal K, Ahlner-Elmqvist M, Jannert M, Kaasa S, Sullivan M, et al.Prospective, longitudinal quality-of-life study of patients with head and neck cancer: a feasibility study including the EORTC QLQ-C30. Otolaryngology Head and Neck Surgery 1997;116(6 Pt 1):666-73.
17. Harari 2005 Harari PM. Promising new advances in head and neck radiotherapy. Annals of Oncology 2005;16 Suppl 6:vi13-vi19.
18. Hassan 1993 Hassan SJ, Weymuller EA. Assessment of quality of life in head and neck cancer patients. Head & Neck 1993;15(6):485- 96.
19. Higgins 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons, Ltd, 2006.
20. Hindle 1996 Hindle I, Downer MC, Speight PM. The epidemiology of oral cancer. British Journal of Oral and Maxillofacial Surgery 1996;34(5):471-6.
21. Kogevinas 1997 Kogevinas M, Pearce N, Susser M, Boffetta P, editors. Social inequalities and cancer. Lyon: IARC Scientific Publications No 138. International Agency for Research in Cancer, 1997.
22. La Vecchia 1997 La Vecchia C, Tavani A, Franceschi S, Levi F, Corrao G, Negri E. Epidemiology and prevention of oral cancer. Oral Oncology 1997;33(5):302-12.
23. Macfarlane 1995 Macfarlane GJ, Zheng T, Marshall JR, Boffetta P, Niu S, Brasure J, et al.Alcohol, tobacco, diet and the risk of oral cancer: a pooled analysis of three case-control studies. Oral Oncology 1995;31B(3):181-7.
24. Modjtahedi 2005 Modjtahedi H. Molecular therapy of head and neck cancer. Cancer Metastasis Reviewes 2005;24(1):129-46.
25. Oliver 2005 Oliver RJ, Clarkson JE, Conway D, Coulthard P, Glenny AM, Hooper L, et al.Interventions for the treatment of oral cancer. Cochrane Database of Systematic Reviews 2005, Issue 4.Art. No.: CD005510. DOI:10.1002/14651858.CD005510.
26. Oliver 2006 Oliver RJ, Clarkson JE, Conway D, Glenny AM, Macluskey M, Pavitt S, et al.Interventions for the treatment of oral cancer: surgical treatment. Cochrane Database of Systematic Reviews 2006, Issue 4.Art. No.: CD006205. DOI:10.1002/14651858.CD006205.
27. Oliver 2007a Oliver RJ, Clarkson JE, Conway D, Glenny AM, Macluskey M, Pavitt S, et al.Interventions for the treatment of oral cancer: chemotherapy. Cochrane Database of Systematic Reviews 2007, Issue 1.Art. No.: CD006386. DOI:10.1002/14651858.CD006386.
28. Oliver 2007b Oliver RJ, Clarkson JE, Conway D, Glenny AM, Macluskey M, Pavitt S, et al.Interventions for the treatment of oral cancer: radiotherapy. Cochrane Database of Systematic Reviews 2007, Issue 1.Art. No.: CD006387. DOI:10.1002/14651858.CD006387.
29. Parkin 1999 Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. International Journal of Cancer 1999;80(6):827-41.
30. Parkin 2001 Parkin D. Global cancer statistics in the year 2000. Lancet Oncology 2001;2(9):533-43.
31. Parkin 2005 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2005;55(2):74-108.
32. Parmar 1998 Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
33. Partridge 2000 Partridge M, Li SR, Pateromichelakis S, Francis R, Phillips E, Huang XH, et al.Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. Clinical Cancer Research 2000;6(7):2718-25.
34. Pentenero 2005 Pentenero M, Gandolfo S, Carrozzo M. Importance of tumor thickness and depth of invasion in nodal involvement and prognosis of oral squamous cell carcinoma: a review of the literature. Head & Neck 2005;27(12):1080-91.
35. Pfister 2006 Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, et al.Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. Journal of Clinical Oncology 2006;24(7):1072-8.
36. Robinson 2003 Robinson KL, Macfarlane GJ. Oropharyngeal cancer incidence and mortality in Scotland: are rates still increasing?. Oral Oncology 2003;39(1):31-6.
37. Rogers 2002 Rogers SN, Lowe D, Fisher SE, Brown JS, Vaughan ED. Health-related quality of life and clinical function after primary surgery for oral cancer. British Journal of Oral and Maxillofacial Surgery 2002;40(1):11-8.
38. Ryan 2005 Ryan AJ, Wedge SR. ZD 6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. British Journal of Cancer 2005;92Suppl 1:S6-13.
39. Shah 1990 Shah JP. Cervical lymph node metastases - diagnostic, therapeutic, and prognostic implications. Oncology (Williston Park, NY) 1990;4(10):61-9.
40. WHO 1992 World Health Organization (WHO). ICD-O. International statistical classification of diseases and related health problems, 1989 revision. Geneva: World Health Organization, 1992.
41. Woolgar 2003 Woolgar J, Rogers SN, Lowe D, Brown JS, Vaughan ED. Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. Oral Oncology 2003;39(2):130-7.
42. Xi 2003 Xi S, Grandis JR. Gene therapy for the treatment of oral squamous cell carcinoma. Journal of Dental Research 2003;82(1):11- 6.
43. Yu 2007 Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Current Cancer Drug Targets 2007;7(2):141-8.